Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now small index

Polypharmacy clinical trials

3 of 12 indexed Polypharmacy trials are currently recruiting.

Corpus placement: #1,429 of 28,707 conditions by registered trial count.

12 US clinical trials · 3 currently recruiting · #1,429 of 28,707 conditions by registered trial count

Polypharmacy: 12 US clinical trials tracked, 3 recruiting.

Polypharmacy is the subject of 12 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. The most active sponsor is Kaiser Permanente, running 2 of these trials.

Enrollment posture brief

Registry condition polypharmacy

OPEN 3 | RECR 25% | LATE 0 | EARLY 0 | RANK #1429 | SPON 2

Nearest open-share peer: Abdominal Cancer (25% recruiting · 8 trials)

Acute Myeloid Leukemia in Re41.7%Adenocarcinoma of the Rectum41.7%Polypharmacy (this)25%Adherence, Patient16.7%Accelerated Phase Chronic My0%
Open-enrollment share among volume-matched conditions near Polypharmacy

Polypharmacy lists 3 open slots (25% of 12 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Polypharmacy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Polypharmacy is recruiting below its size-band peers.

    3 of 12 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Polypharmacy research.

    Kaiser Permanente accounts for 2 of 12 trials (16.7%). 11 distinct sponsors appear on at least one study for this condition label.

  3. Typical Polypharmacy enrolment sits around 786 participants.

    Median target enrolment is 786 among the 12 trials that report a genuine target (sentinel values excluded). 4 of those (33.3%) plan for fewer than 100 participants.

  4. Polypharmacy research is mostly interventional.

    11 interventional and 1 observational studies make up this index (91.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Open and recent trials

12 total, page 1 of 1

RECRUITING 3,000 participants

Interprofessional Pharmacogenomics (IPGx) Registry and Repository

Texas A&M University

NCT06726590

RECRUITING NA 1,000 participants

The Geriatric Emergency Department Pharmacologic Harm Prevention Project

Florida Atlantic University

NCT07216846

RECRUITING NA 50 participants

Improving Medication Management in World Trade Center Responders

Icahn School of Medicine at Mount Sinai

NCT07022990

ACTIVE NOT RECRUITING NA 6,478 participants

Pharmacist Intervention to Reduce Post-Hospitalization Utilization

Cedars-Sinai Medical Center

NCT04071951

ACTIVE NOT RECRUITING NA 2,000 participants

Preemptive Pharmacogenomics Testing Among Geriatric Patients

Geisinger Clinic

NCT05091879

ACTIVE NOT RECRUITING NA 786 participants

Reducing High-Risk Geriatric Polypharmacy Via EHR Nudges R01 Trial

Northwestern University

NCT05656560

ACTIVE NOT RECRUITING NA 600 participants

Effectiveness of PGx Testing

Kaiser Permanente

NCT04120480

COMPLETED NA 2,471 participants

Bundled Hyperpolypharmacy Deprescribing

Kaiser Permanente

NCT05616689

COMPLETED NA 372 participants

A Randomized Controlled Trial to Deprescribe for Older Patients With Polypharmacy

Vanderbilt University Medical Center

NCT02979353

COMPLETED NA 33 participants

Tailored Medication Management Intervention

Washington University School of Medicine

NCT04717297

COMPLETED NA 23 participants

Standardized Patient-Centered Medication Review in Home Hospice

University of Massachusetts, Worcester

NCT03972163

COMPLETED NA 18 participants

Adapting the Shed-MEDS Deprescribing Intervention to Dementia Care in Assisted Living

Vanderbilt University

NCT05956665

Phase Distribution

Phase data not available

Named interventions

Most-linked intervention names on Polypharmacy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Bundled hyperpolypharmacy Other
1 trials
Shed-MEDS deprescribing intervention Behavioral
1 trials
Medication Management In-Person Intervention Behavioral
1 trials
Medication Management Remote Intervention Behavioral
1 trials
"Key Approaches to Support Informal Family Caregivers in Managing Medications" Behavioral
1 trials
"Discontinuing Medication Appropriately" and "Understanding the Art of Communication about Deprescribing" Behavioral
1 trials
STOPPFrail (Screening Tool of Older Persons Prescriptions) Behavioral
1 trials
NIA Medication Management - Active Comparator Behavioral
1 trials

US sites by state

Facility locations filed on Polypharmacy trials. A trial with sites in several states counts in each.

Tennessee 2 trials
Pennsylvania 2 trials
Massachusetts 2 trials
California 2 trials
Texas 1 trials
New York 1 trials
Missouri 1 trials
Illinois 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Polypharmacy page

12 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Polypharmacy condition card totals 12 registered trials; most-linked intervention Bundled hyperpolypharmacy; top US site state Tennessee. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.